WuXi Biologics leases U.S. manufacturing facility

By The Science Advisory Board staff writers

June 9, 2020 -- Hong Kong-based WuXi Biologics has signed a 10-year lease for a clinical manufacturing facility in Cranbury, NJ, making it the company's third site in the U.S.

The company will install 6,000-L bioreactors for manufacturing, process development and quality control labs, and associated functional spaces. The 66,000-sq-ft facility is expected to open in late 2020 and will bring 100 new jobs to the region.

WuXi recently purchased land to build a 107,000-sq-ft facility in Worcester, MA, and leased a 33,000-sq-ft site for process development in King of Prussia, PA.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.